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Abstract
Introduction:  Obstructive  sleep  apnea  syndrome  (OSAS)  is  associated  with  cardiovascu-
lar/metabolic  complications.  Some  analytical  parameters  (homocysteine,  glycemic  and  lipidic
proﬁles) are  recognized  markers  of  these  consequences.  Limited  data  is  available  on  the  asso-
ciation of  these  markers  and  OSAS’s  severity/response  to  positive  airway  pressure  therapy
(PAP).
Material  and  methods:  In  this  prospective  study  we  analyzed  polysomnographic  and  ana-
lytical data  of  male  patients  admitted  to  sleep  laboratory.  The  aim  was  to  evaluate
metabolic/cardiovascular  markers  in  snorers  and  OSAS  patients,  to  relate  with  sleep  param-
eters and  PAP  response.  One-hundred  and  three  patients  were  included,  and  73  (71%)  were
OSAS patients.  OSAS  patients  were  similar  to  snorers  except  for  higher  body  mass  index
(BMI) and  dyslipidemia.  Severe  OSAS  patients  showed  higher  glycemia,  HbA1c,  insulin,  and
er  HDL  cholesterol  in  comparison  to  mild--moderate  (p  <  0.05,
1,  p  <  0.05,  respectively).  Glycemic  proﬁle  and  triglycerides  were
AS  severity.  46  OSAS  patients  were  submitted  to  6  months  of  PAP,insulin resistance,  and  low
p <  0.05,  p  <  0.001,  p  <  0.00
slightly correlated  with  OS∗ Corresponding author.
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with  a  statistical  decrease  in  mean  values  of  homocysteine,  glycemia,  total  and  LDL  cholesterol
(p <  0.05,  p  <  0.05,  p  <  0.05,  respectively),  and  in  glycemia  and  LDL  cholesterol  in  severe  group
only (p  <  0.05,  p  <  0.05,  respectively).
Results:  This  study  demonstrated  an  association  between  glucose  metabolism  parameters  and
triglycerides  with  OSAS  severity  underlying  the  complexity  of  the  process  leading  to  cardiovas-
cular/metabolic  complications  in  this  disorder.  Moreover,  homocysteine,  glycemic  and  lipidic
proﬁles changed  signiﬁcantly  after  6  months  of  PAP  therapy  in  OSAS,  supporting  its  cardiovas-
cular and  metabolic  protective  effect.
Conclusion:  Our  study  has  reinforced  the  importance  of  analytical  cardiovascular/metabolic
evaluation  as  complementary  tool  of  diagnosis/treatment  response  in  OSAS.
© 2017  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
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bstructive  sleep  apnea  syndrome  (OSAS)  is  a  com-
on  sleep  and  chronic  respiratory  disorder,1,2 associated
ith  cardiovascular3--5 and  metabolic  (such  as  obesity,6
yslipidemia7 and  type  2  diabetes)8 complications.  It  has
een  difﬁcult  to  determine  if  these  are  due  to  OSAS  or  to
ssociated  risk  factors.  Sleep  fragmentation  and  intermit-
ent  hypoxia  are  some  mechanisms  contributing  to  OSAS
omplications,9,10 which  improve  with  positive  airway  pres-
ure  treatment  (PAP).  However,  the  impact  of  PAP  on
ther  mechanisms  involved  is  still  not  well  characterized.
ome  oxidative  stress  biomarkers  have  been  associated  to
SAS  morbidity.11 Still  controversy  remains  regarding  the
est  diagnostic/prognostic  marker.  An  example  is  homocys-
eine  (Hcy),  which  is  considered  a  ‘‘promising’’  marker.12
cy  is  an  intermediate  product  in  the  biosynthesis  of
ethionine  and  cysteine,13 and  is  determinant  of  the  meth-
lation  cycle.14 Hcy  levels  in  adults  follow  a  circadian
ariation,15 being  lower  in  the  morning.  Studies  reported
cy  as  an  independent  risk  factor  for  atherosclerosis,16,17
erebral,  and  cardiovascular  diseases  (CVD),13,18--24 being
elated  with  their  prognosis.18 The  proposed  mechanisms
re  its  adverse  effects  on  vascular  structure  and  function,25
ypercoagulability  state,23 and  depletion  of  nitric  oxide.26
oreover,  dyslipidemia,  diabetes,  cancer,  renal,  and  thyroid
ysfunction13,23 are  associated  with  elevated  Hcy.  Also,  older
ge,  male  gender,  various  drugs,  tobacco/coffee/alcohol,
nd  vitamins  deﬁciency.13,23 Hcy  has  been  proposed  as  an
SAS  biomarker  regarding  its  relationship  with  CVD.  Studies
how  higher  levels  of  Hcy  in  OSAS  with27--30 or  without31,32
re-existing  cardiac  disease.  Moreover  there  are  contradic-
ory  studies  reporting  the  effect  of  PAP  on  Hcy  levels.29,33--37
The  aim  of  this  study  was  to  analyze  Hcy  levels  in  snorers
nd  OSAS  patients,  its  correlation  with  OSAS  severity,  and
esponse  to  PAP.  Additionally,  glycemic  and  lipid  parameters
ere  also  evaluated.
aterial and methodshis  prospective  study  included  one  hundred  three  con-
ecutive  male  subjects  with  suspicion  of  OSAS,  who  were
valuated  at  a  Sleep  Clinic.  Demographic  data  included
ge,  body  mass  index  (BMI),  Epworth  sleepiness  scale,  and
a
t
p
bedical  history.  Exclusion  criteria  were  female  gender  (to
void  hormonal  inﬂuence),  other  sleep  disorders,  neuromus-
ular,  renal,  and  thyroid  disease,  heart  failure,  cancer,  acute
isease,  and  previous  PAP.
All  patients  underwent  an  overnight  polysomnography
PSG)  using  Embla  S7000  System  (Embla,  USA)  with  a  techni-
ian  monitoring.  Sleep  recording  and  events  were  manually
nalyzed  according  to  standard  criteria.38 The  respiratory
isturbance  index  (RDI),  oxygen  desaturation  index  (ODI),
ercentage  of  time  with  saturation  under  90%  (T90)  and
owest  oxygen  saturation  (SpO2) were  calculated.  Based
n  RDI  ≥  5  obstructive  events/h  of  sleep,  patients  were
iagnosed  as  OSAS  (n  =  73)  and  grouped  into  mild  (RDI
--14.9),  moderate  (RDI  15--29.9),  and  severe  (RDI  ≥  30).
ater,  in  pre/post  OSAS  treatment  analysis,  mild  and  moder-
te  patients  were  combined  (RDI  <  30),  in  order  to  evaluate
he  extreme  of  disease  spectrum.
To  calculate  the  sample  size  we  focused  in  the  main
bjective,  that  is  Hcy  analysis  before/after  PAP  treatment.
he  sample  size  was  calculated  with  PS  software,  version
.1.2.  It  was  planned  a  study  of  a  continuous  response
ariable  from  matched  pairs  of  study  subjects.  Prior  data
ndicated  that  the  difference  in  the  response  of  matched
airs  was  normally  distributed  with  standard  deviation  2.  If
he  true  difference  in  the  mean  response  of  matched  pairs
s  0.95,  the  sample  size  need  to  be  of  37  pairs  of  subjects  to
e  able  to  reject  the  null  hypothesis  that  this  response  dif-
erence  is  zero  with  probability  (power)  0.8  (i.e.  beta  0.20).
he  type  I  error  probability  associated  with  this  test  of  this
ull  hypothesis  is  0.05  (i.e.  alfa  0.05).
According  to  criteria,39 PAP  therapy  with  automatic
evices  (S9,  Resmed,  Australia)  was  prescribed  for  46
atients  in  severe  disease  or  in  disease  of  any  severity
hen  associated  with  excessive  diurnal  sleepiness  and/or
ardio/cerebrovascular  complications.  These  patients  were
valuated  at  six  months  for  compliance  registration.  As
escribed,41 more  than  4  h  use/night  for  at  least  70%  of
ights  was  considered  as  acceptable  compliance.  After  PAP
nitiation,  no  more  indications  (excluding  healthy  lifestyle)
ere  given,  assuming  a  real  life  scenario.
Venous  blood  samples  were  collected  after  PSG  and
 12-h  fasting  period,  into  EDTA-coated  polypropylene
ubes.  At  six  months  of  PAP  a  second  morning  blood  sam-
le  was  collected.  The  collected  blood  was  processed
etween  1  and  2 h  to  determine  Hcy  (chemiluminescence
r  and
u
s
g
O
i
G
e
H
(
w
p
u
(
o
s
c
m
g
I
s
D
T
t
p
r
a
t
t
B
c
s
b
l
p
B
o
p
s
o
i
y
h
h
w
f
w
u
r
i
A
iEffects  of  positive  airway  pressure  therapy  on  cardiovascula
(CLIA),  ADVIA  Centaur  xp,  Siemens).  Additionally,  param-
eters  of  glycemic  proﬁle  were  determined,  such  as
glucose  (Enzyme  UV  Hexoquinase  --  ADVIA  2400  Siemens),
haemoglobin  A1c  (HbA1c)  (HPLC  --  Variant  II  BioRad),
insulin  (chemiluminescence  (CLIA),  ADVIA  Centaur  xp,
Siemens)  and  insulin  resistance  (calculated  by  homeo-
static  model  assessment  of  insulin  resistance  --  HOMA-IR).
Parameters  of  lipid  proﬁle  were,  also,  determined  such  as
total  cholesterol  (CHOD-PAP  (enzymatic  colorimetric)  ADVIA
2400,  Siemens),  low-density  lipoprotein  (LDL)  cholesterol
(by  calculation),  high-density  lipoprotein  (HDL)  cholesterol
(HDL  Plus  2nd  generation  elimination/catalase  ADVIA  2400,
Siemens),  and  triglycerides  (Enzymatic  colorimetric  (GPO)
ADVIA  2400,  Siemens).  The  HOMA-IR  was  determined  by
the  product  between  fasting  plasma  glucose  and  insulin
concentration,  which  has  a  reasonable  linear  correlation
with  the  gold  standard  of  insulin  resistance  measurement
(hyperinsulinemic--euglycemic  clamp).40
All  subjects  underwent  restriction  of  alcohol,  tea,  cof-
fee,  chocolate,  beetroot,  banana,  avocado,  tomato,  plum,
pineapple,  kiwi,  orange,  nut,  hazelnut,  vanilla  candies,  and
confectionery  during  the  three  days  prior  to  PSG.  Patients
underwent  24  h  urine  collection  (into  a  hydrochloric  acid
container  and  stored  at  4 ◦C)  for  catecholamines  determi-
nation  (adrenaline,  nor-adrenaline,  and  dopamine)  (HPLC  --
BioRad).
The  study  protocol  was  approved  by  the  local  ethics  com-
mittees  and  all  patients  gave  written  informed  consent.
Statistical  analyses  were  performed  using  SPSS  for
windows  software  (SPSS  20  Inc.,  Chicago,  IL,  USA).  All  varia-
bles  were  tested  for  normality  of  the  distribution  using
Kolmogorov--Smirnov  test.  Continuous  variables  with  normal
distributions  were  expressed  as  means  ±  standard  deviation
(SD)  and  categorical  variables  in  numbers  (percentages).
Pearson’s  analysis  was  performed  for  correlations  between
parametric  variables.  Independent-samples  T-test  was  used
for  comparisons  between  independent  groups  for  values  that
were  normally  distributed  and  paired-samples  T-test  was
used  to  compare  variables  normally  distributed  before  and
after  PAP  treatment.  Categorical  variables  were  compared
using  X2 test.  Results  were  considered  statistically  signiﬁ-
cant  when  p  value  was  <0.05.
Results
Clinical  and  analytical  evaluation  of  snorers  and  OSAS
patients  are  shown  in  Table  1.  There  were  no  statistically
signiﬁcant  differences  regarding  demographic  and  analytical
parameters.  Instead,  the  existence  of  known  dyslipidemia
and  BMI  were  higher  in  OSAS  patients  (p  <  0.001,  p  =  0.001,
respectively).  HOMA-IR,  total  cholesterol,  and  urinary  nor-
adrenaline  were  higher  than  normal  range  in  OSAS  patients
and  Hcy  was  higher  than  normal  range  in  both  groups.
Concerning  OSAS  patients,  there  were  no  statistically
differences  between  mild--moderate  (46,  63%)  and  severe
(27,  37%)  regarding  demographic  parameters.  Instead,  dys-
lipidemia  and  BMI  were  higher  in  severe  OSAS  patients
(p  <  0.05,  p  < 0.001,  respectively).  Glycemia,  HbA1c,  insulin,
and  HOMA-IR  were  higher  and  HDL  cholesterol  was  lower  in
severe  group  (p  <  0.05,  p  <  0.05,  p  <  0.001,  p  <  0.001,  p  <  0.05,
respectively).  Moreover,  HbA1c,  HOMA-IR,  triglycerides,  and
m
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rinary  catecholamines  were  higher  than  normal  range  in
evere  OSAS  patients  and  total  cholesterol  and  Hcy  in  both
roups.
Some  metabolic  parameters  were  slightly  correlated  with
SAS  severity.  Glycemia,  HbA1c,  and  triglycerides  were  pos-
tively  correlated  with  RDI  (p  <  0.05,  Pearson  correlation).
lycemia  and  HbA1c  were  negatively  correlated  with  low-
st  SpO2 (p  <  0.05,  Pearson  correlation).  Instead,  insulin  and
OMA-IR  were  positively  correlated  with  RDI,  T90,  and  ODI
p  <  0.001,  Pearson  correlation)  and  negatively  correlated
ith  lowest  SpO2 (p  <  0.001)  (Table  2).
Clinical  and  analytical  evaluation  of  OSAS  treatment
atients  are  shown  in  Tables  1  and  3.  46  OSAS  patients
nderwent  PAP  (22  (48%)  were  mild--moderate  and  24
52%)  were  severe).  Patients  showed  a  mean  compliance
f  4.37  h/night.  Additionally  in  PAP  follow  up,  weight  and
moking  habits  were  always  asked  and  there  were  no
hanges  in  both  parameters.  After  six  months  of  treat-
ent,  OSAS  patients  showed  a  statistical  decrease  in  Hcy,
lycemia,  total  and  LDL  cholesterol  (p  <  0.05)  (Table  3).
nstead,  in  severe  OSAS  only  glycemia  and  LDL  cholesterol
howed  a  signiﬁcant  reduction  (p  <  0.05).
iscussion
his  study  showed  after  six  months  of  PAP,  homocys-
eine,  glycemia,  total  and  LDL  cholesterol  decrease  in  OSAS
atients  pointing  to  cardiovascular/metabolic  protective
ole  of  this  treatment.
In  our  study,  Hcy  was  similar  in  snorers  and  OSAS  patients,
nd  also  in  different  OSAS  severities,  although  being  higher
han  normal  range.  Hcy  is  an  emerging  independent  risk  fac-
or  for  CVD,  but  it  is  not  clear  its  association  with  OSAS.
oth  smoking  and  obesity  may  affect  Hcy  levels,42--47 which
ould  be  confounders  in  the  association  with  CVD.  In  this
tudy,  smoking  habits  and  prevalence  of  CVD  were  similar
etween  snorers  and  OSAS  patients,  and  between  different
evels  of  OSAS  severity.  Concerning  obesity,  snorers  and  OSAS
atients  were  obese,  still  OSAS  patients  presented  a  higher
MI,  which  could  inﬂuence  the  Hcy  levels.  The  presence  of
besity  even  in  snorers  is  probably  responsible  for  OSAS  sus-
icion  and  referral  to  sleep  clinic.48 Also,  several  diseases
uch  as  dyslipidemia13,23 are  associated  with  elevated  levels
f  Hcy,  and  this  disease  was  more  prevalent  in  OSAS  patients.
A  meta-analysis  (432  subjects)  showed  higher  Hcy  levels
n  OSAS  than  in  controls,49 especially  when  BMI  ≥  30,  age  <  50
ears,  and  severe  OSAS.  Other  authors50,51 also  reported
igher  Hcy  levels  in  severe  OSAS.  A  recent  study  reported
igher  Hcy  levels  in  patients  with  coronary  artery  disease,
ith  OSAS  and  with  both  diseases,30 and  the  highest  values
or  Hcy  were  observed  in  the  latter  group.  Further,  there
as  no  correlation  between  Hcy  levels  and  oxygen  desat-
ration,  as  showed  in  the  present  study.  Contrary  to  these
esults,  some  studies  did  not  report  increased  levels  of  Hcy
n  OSAS  patients  with34,35 or  without  associated  CVD.28,29,36
lthough,  Hcy  was  not  correlated  with  sleep  parameters,
n  OSAS  patients  it  decreased  for  normal  values  after  6
onths  of  PAP  therapy,  which  may  suggest  that  its  levels
ould  in  part  be  related  with  OSAS.  These  results  are  similar
o  a  study  of  12  OSAS  patients  with  CVD,  which  reported  a
eduction  in  Hcy  levels  after  PAP  therapy.33 This  behaviour
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Table  1  Initial  evaluation  of  study  participants:  demographics,  comorbidities,  polysomnography  data,  glycemic  and  lipidic  proﬁles,  homocysteine,  and  urinary  catecholamines
(BMI: body  mass  index;  EPW:  Epworth  sleepiness  scale;  LDL:  low-density  lipoprotein;  HDL:  high-density  lipoprotein;  HOMA-IR:  homeostasis  model  assessment;  OSAS:  obstructive
sleep apnea  syndrome;  RDI:  respiratory  disturbance  index;  SD:  standard  deviation;  T90:  desaturation  time  under  90%;  U:  urine).
Total  Snorers  OSAS  Snorers  vs.
OSAS  (p)
Mild-Mod
OSAS
Severe  OSAS  Mild-Mod  vs.
Severe  OSAS
(p)
Mild-Mod
OSAS  before
PAP
Severe  OSAS
before  PAP
Mild-Mod  vs.
severe  OSAS
before  PAP
(p)
N =  103  N  =  30  N  =  73  N  =  46  N  =  27  N  =  22  N  =  24
Age  (years)
(media/SD)
46/8  45/10  46/8  0.354  46/8  47/7  0.737  47/9  47/7  0.931
Smoking history  (n/%) 69/67.0  21/70.0  48/65.8  0.681  29/63.0  19/70.4  0.531  14/63.6  17/70.8  0.612
Alcohol consumption
(n/%)
66/64.1  15/50.0  51/69.9  0.057  30/65.2  21/77.8  0.265  15/68.2  18/75.0  0.617
BMI (kg/m2)
(media/SD)
29.4/3.8  27.4/3.3  30.2/3.7  0.001  28.9/3.0  32.3/3.8  <0.001  29.4/2.4  32.0/3.7  0.006
Cardiac disease  (n/%)  55/53.4  13/43.3  42/57.5  0.193  23/50.0  19/70.4  0.092  12/54.5  17/70.8  0.263
Respiratory disease
(n/%)
15/14.6  2/6.7  13/17.8  0.188  7/15.2  6/22.2  0.571  3/13.6  6/25.0  0.382
Dyslipidemia (n/%)  49/47.6  4/13.3  45/61.6  <0.001  22/47.8  23/85.2  0.026  10/45.5  20/83.3  0.030
Diabetes (n/%)  7/6.8  1/3.3  6/8.2  0.374  2/4.3  4/14.8  0.115  0/0  3/12.5  0.099
EPW scale  (media/SD) 9.5/4.8  9.3/5.1  9.5/4.7  0.843  9.7/4.7  9.2/4.8  0.694  11.7/4.1  9.5/5.0  0.103
RDI (events/h)
(media/SD)
20.4/23.3  2.8/1.3  27.6/24.2  <0.001  11.9/6.1  54.3/19.5  <0.001  12.2/6.2  55.0/19.3  <0.001
T90 (%)  (media/SD)  5.6/13.2  1.6/8.1  7.2/14.5  0.047  1.0/2.3  17.9/19.6  <0.001  1.2/2.0  16.4/18.2  <0.001
Sleep efﬁciency  (%)
(media/SD)
79.2/14.4  77.3/14.4  79.1/14.5  0.407  80.4/14.7  79.1/14.0  0.703  75.2/18.6  77.2/13.8  0.675
Lowest SpO2  (%)
(media/SD)
84.1/7.5  88.5/4.6  82.3/7.7  <0.001  85.3/5.4  77.1/8.3  <0.001  83.3/6.6  77.7/7.8  0.012
ODI
(dessaturations/h)
(media/SD)
16.8/22.5 2.2/2.9  22.8/24.2  <0.001  8.1/5.7  47.8/23.2  <0.001  8.9/6.0  48.1/23.8  <0.001
Glucose (mg/dL)
(media/SD)
101.0/25.8  101.2/31.3  100.9/23.4  0.951  95.9/17.2  109.4/29.8  0.017  97.3/20.2  109.4/31.0  0.128
Glycosylated
haemoglobin (%)
(media/SD)
5.8/0.8  5.8/1.0  5.8/0.8  0.957  5.6/0.5  6.1/1.0  0.012  5.6/0.7  6.2/1.0  0.036
Insulin (mU/L)
(media/SD)
14.7/8.6  12.7/6.8  15.5/9.1  0.124  12.4/6.8  20.9/10.1  <0.001  11.3/5.0  20.8/10.4  <0.001
HOMA-IR (media/SD)  3.8/2.8  3.3/2.8  4.0/2.8  0.241  3.1/2.2  5.7/2.9  <0.001  2.8/1.7  5.6/2.9  <0.001
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Table  1  (Continued)
Total Snorers  OSAS  Snorers  vs.
OSAS  (p)
Mild-Mod
OSAS
Severe  OSAS Mild-Mod  vs.
Severe  OSAS
(p)
Mild-Mod
OSAS  before
PAP
Severe  OSAS
before  PAP
Mild-Mod  vs.
severe  OSAS
before  PAP
(p)
N =  103 N  =  30 N  =  73 N  =  46 N  =  27 N  =  22 N  =  24
Total  cholesterol
(mg/dL)
(media/SD)
192.1/37.7  185.9/41.3  194.6/36.1  0.290 194.2/38.4  195.3/32.4  0.092 191.6/42.7  193.7/30.0  0.852
LDL cholesterol
(mg/dL)
(media/SD)
121.0/31.6  117.2/33.4  122.6/30.9  0.435 122.1/30.6  123.5/32.0  0.854 123.8/32.6  122.0/28.2  0.850
HDL cholesterol
(mg/dL)
(media/SD)
44.7/10.1  44.7/10.4  44.7/10.0  1.000 46.8/11.3  41.2/6.0  0.019  44.6/12.3  41.0/5.5  0.190
Triglycerides (mg/dL)
(media/SD)
134.6/79.3  121.0/68.0  140.2/83.3  0.265 128.8/79.4  159.7/87.6  0.126 120.0/57.1  160.7/88.7  0.074
Homocysteine
(mol/L)
15.2/3.4 14.7/3.3  15.3/3.5  0.399 15.3/3.8  15.3/2.9  0.997 14.9/3.1  15.6/2.6  0.436
Adrenaline (g/24  h
U)  (media/SD)
19.9/15.5  17.7/16.3  20.8/54.2  0.765 13.8/12.3  32.7/87.4  0.152 14.2/13.1  34.7/92.6  0.308
Noradrenaline
(g/24 h  U)
(media/SD)
85.7/180.4  64.6/28.1  94.3/213.4  0.45 63.1/35.5  147.5/345.4  0.103 62.0/35.4  149.7/365.9  0.269
Dopamine (g/24  h  U)
(media/SD)
434.6/771.5  373.9/197.0  459.5/908.5  0.611  340.9/202.1  661.5/1465.5  0.147  334.7/220.4  657.2/1550.0  0.339
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Table  2  Correlation  between  variables  of  polysomnography  and  glycemic  and  lipidic  proﬁles,  homocysteine,  and  urinary  cate-
cholamines (LDL:  low-density  lipoprotein;  HDL:  high-density  lipoprotein;  HOMA-IR:  homeostasis  model  assessment;  ODI:  oxygen
desaturation  index;  RDI:  respiratory  disturbance  index;  T90:  desaturation  time  under  90%;  U:  urine).
Glucose  (mg/dL) Glycosylated  haemoglobin  (%) Insulin  (mU/L) HOMA-IR
r  p  r  p  r  p  r  p
RDI  (events/h) 0.217 0.027 0.217 0.028  0.423  <0.001  0.382  <0.001
T90 (%) 0.179 0.071 0.121 0.224 0.342  <0.001  0.331  0.001
Sleep efﬁciency  (%) 0.01 0.923 0.018 0.857 0.009 0.925 0.061 0.539
Lowest  SpO2  (%)  0.264  0.007  0.242  0.014  0.321  0.001  0.372  <0.001
ODI (dessaturations/h)  0.181  0.068  0.172  0.083  0.428  <0.001  0.384  <0.001
Total cholesterol  (mg/dL)  LDL  cholesterol  (mg/dL)  HDL  cholesterol  (mg/dL)  Triglycerides  (mg/dL)
r  p  r p  r  p  r  p
RDI  (events/h) 0.087 0.385 0.056  0.577  0.123  0.215  0.205  0.038
T90 (%) 0.133 0.180 0.111  0.267  0.021  0.833  0.154  0.122
Sleep efﬁciency  (%) 0.115 0.246 0.126 0.206  0.012  0.908  0.002  0.986
Lowest SpO2  (%) 0.110 0.269 0.079 0.432 0.008  0.937  0.141  0.155
ODI (dessaturations/h) 0.094 0.343 0.081 0.421  0.119  0.229  0.175  0.076
Homocysteine  (mol/L)  Adrenaline  (g/24  h  U)  Noradrenaline  (g/24  h  U)  Dopamine  (g/24  h  U)
r  p  r  p  r  p  r  p
RDI  (events/h)  0.028  0.782  0.083  0.407  0.107  0.284  0.08  0.42
T90 (%)  0.083  0.405  0.045  0.651  0.028  0.78  0.001  0.99
Sleep efﬁciency  (%)  0.135  0.176  0.095  0.342  0.052  0.61  0.033  0.744
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eLowest SpO2  (%)  0.001  0.992  0.029  0.773
ODI (dessaturations/h)  0.056  0.577  0.024  0.81  
nder  PAP  was  conﬁrmed  in  a  recent  meta-analysis.52 On
he  contrary,  other  studies29,35--37 reported  that  PAP  therapy
r  mandibular  advancement  device37 did  not  inﬂuence  Hcy
evels  in  OSAS  patients.
Previous  studies  suggest  that  OSAS  is  associated  with
yslipidemia7 and  type  2  diabetes.8 In  fact,  in  this  study  dys-
ipidemia  was  more  prevalent  in  OSAS  patients  comparing  to
norers,  although  both  groups  showed  similar  glycemic  and
ipid  proﬁles.
Indeed,  some  authors  found  that  OSAS  is  independently
ssociated  with  disorders  of  lipid  metabolism,53 mainly  due
o  intermittent  hypoxia54 and  sleep  fragmentation.55 Fur-
hermore,  as  in  this  study,  triglycerides  were  associated  with
SAS  severity.53 This  is  an  important  issue  once  dyslipidemia
s  a  major  cause  of  atherosclerotic  CVD.56
Moreover,  severe  OSAS  showed  a  change  in  glycemic
roﬁle,  even  in  absence  of  known  diabetes,  probably  sug-
esting  a  pre-diabetic  state,  and  it  was  correlated  with  sleep
arameters  (RDI  and  nocturnal  desaturation).  A  condition
haracterized  by  insulin  resistance  and  glucose  intolerance
s  known  as  prediabetes.57 Individuals  presenting  this  state
re  at  risk  of  CVD  and  the  majority  will  develop  diabetes,58,59
utting  our  severe  patients  in  an  increased  risk  for  both  dis-
rders.  These  results  are  in  agreement  with  a  meta-analysis
hich  conﬁrmed  that  moderate/severe  OSAS  increases  the
isk  of  development  of  type  2  diabetes,60 even  following
djustment  of  obesity,  age,  co-morbidities,  and  medication
se.61 Sleep  fragmentation  and  intermittent  hypoxia62
eem  to  be  involved  in  carbohydrate  dysregulation  in
SAS,  with  impaired  lipid  metabolism,  inﬂammation,
p
a
r
a0.044  0.659  0.013  0.899
0.053  0.592  0.029  0.77
xidative  stress  and  sympathetic  nervous  system
ctivation.63
Concerning  the  evaluation  of  both  proﬁles  after  PAP
herapy,  OSAS  patients  presented  a  statistical  change  in
lycemic  and  lipid  proﬁles,  with  a decrease  in  glucose,  total
nd  LDL  cholesterol.  Some  trials  provide  evidence  that  PAP
herapy  may  improve  glucose  metabolism64 especially  in
leepy  patients.65 However,  other  studies  do  not  support  this
mprovement,66 but  the  duration  of  treatment  could  be  an
xplanation.  A  recent  study  has  shown  improvement  in  glu-
ose  metabolism  with  PAP  therapy  even  in  OSAS  patients
overweight  or  obese)  with  prediabetes.67 Additionally,  even
n  non-diabetic  adults  with  OSAS,  two  meta-analyses  have
eported  that  PAP  therapy  modestly  decreases  HOMA-IR.68,69
nother  study  in  diabetic  OSAS  patients  has  shown  that  one
onth  of  PAP  therapy  led  to  reduction  of  fasting  glucose,
bA1c,  and  HOMA-IR,  without  change  in  BMI.70
A  meta-analysis  reported  that  PAP  therapy  decreases
otal  cholesterol  level,  especially  in  OSAS  patients  who
re  younger,  more  obese,  and  who  use  PAP  for  a  longer
eriod  (≥12  weeks).71 However,  in  this  meta-analysis  PAP
ad  no  effect  on  fasting  glucose  or  HOMA-IR.  Also  in
 meta-regression  analysis,  PAP  improved  total  and  LDL
holesterol,  with  an  increase  in  HDL  cholesterol.7 A  more
ecent  meta-analysis72 reported  that  PAP  signiﬁcantly  low-
red  total  cholesterol,  triglyceride,  and  HDL,  but  not  LDL,
articularly  in  moderate-severe  patients,  good  compliance
nd  daytime  somnolence.  However  the  magnitude  of  lipid
eduction  was  modest  and  only  signiﬁcant  in  studies  where
utonomic  hyperactivity  was  also  lowered  by  PAP.  In  fact,  in
Effects  of  positive  airway  pressure  therapy  on  cardiovascular  and
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he  present  study  OSAS  patients  presented  a  higher  preva-
ence  of  dyslipidemia  and  after  PAP  there  was  a  decrease  in
otal  and  LDL  cholesterol,  without  changing  lifestyle  habits.
oreover,  urinary  cathecolamines  decrease  to  normal  levels,
owever  without  statistical  signiﬁcance,  which  could  have
onditioned  lipid  lowering  effect  of  PAP.
Treatment  with  PAP  in  OSAS  may  improve  dyslipidemia
hrough  ameliorating  hypoxia,  inﬂammation,73 and  insulin
esistance.74 However,  dyslipidemia  in  OSAS  patients  is  far
rom  being  a  simple  process  because,  besides  OSAS  severity,
everal  factors  can  contribute  for  it  such  as  obesity,  diet,  and
xercise.34,53,75,76 This  fact  and  probably  sample  size  could
xplain  that  the  remainder  of  lipidic  proﬁle  (triglyceride,
otal  and  HDL  cholesterol)  was  not  affected  by  PAP  in  this
tudy.
This  study  showed  a  similar  pattern  of  urinary  cate-
holamines  between  snorers  and  OSAS  patients  and  between
SAS  patients  of  different  severities.  Additionally,  in  severe
SAS  patients  urinary  catecholamines  were  higher  than
ormal  range.  Although  urinary  cathecolamines  were  not
orrelated  with  sleep  parameters,  after  six  months  of  PAP,
hey  decreased  to  normal  levels,  nonetheless  without  sta-
istical  signiﬁcance.  These  results  may  be  due  to  sample
ize  because  previous  studies  reported  that  in  OSAS  there
s  an  increase  in  sympathetic  activity,  independently  of
besity.77 In  fact,  Pinto  et  al.78 reported  24-h  urinary  nor-
pinephrine  levels  signiﬁcantly  higher  in  severe  OSAS  than
n  mild--moderate,  with  a  signiﬁcant  reduction  after  one
onth  of  PAP.  Another  study79 reported  that  PAP  with-
rawal  resulted  in  rise  in  urinary  noradrenaline  and  that
as  positively  associated  with  hypoxaemia  severity.  Reduc-
ion  of  sympathetic  activity  can  be  a  potential  mediator  of
etabolic  beneﬁt  from  PAP  (with  improvement  of  glucose
evels)  as  shown  in  a  study  by  Pamidi  et  al.67
There  are  some  limitations  of  this  study,  such  as  small
ample  size,  female  exclusion,  and  BMI  differences  between
roups.  Furthermore,  drugs  and  diseases  that  interfere  with
itamin  B  metabolism  are  potential  causes  for  higher  Hcy
oncentrations,80 and  these  vitamins  were  not  determined
n  this  study.
onclusion
he  present  study  demonstrated  an  association  between  glu-
ose  metabolism  parameters  and  triglycerides  with  OSAS
everity,  contributing  to  the  complexity  of  the  process
eading  to  cardiovascular/metabolic  complications  in  this
isorder.  Moreover,  Hcy,  glycemic,  and  lipid  proﬁles  changed
igniﬁcantly  after  6  months  of  PAP  therapy  in  OSAS  patients,
upporting  its  cardiovascular  and  metabolic  protective
ffect.
In  conclusion,  our  study  has  reinforced  the  importance
f  analytical  cardiovascular/metabolic  evaluation  as  com-
lementary  tool  of  diagnosis/treatment  response  in  OSAS
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